Description: Santen Pharmaceutical Co., Ltd. researches and develops, produces, and markets pharmaceuticals and medical devices in Japan and internationally. It offers prescription pharmaceutical products for glaucoma and ocular hypertension, dry eyes, allergic conjunctivitis, severe keratitis with dry eyes, vernal keratoconjunctivitis, uveitis, wet age-related macular degeneration, and myopia; and over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Home Page: www.santen.com
Grand Front Osaka Tower A
Osaka,
530-8552
Japan
Phone:
81 6 7664 8621
Officers
Name | Title |
---|---|
Mr. Takeshi Ito | President, CEO & Representative Director |
Mr. Kazuo Koshiji | CFO & Corporate Officer |
Ms. Rie Nakajima | COO, Corporate Officer & Director |
Ms. Kaori Itagaki | General Manager of Investor Relations Group |
Ms. Mika Masunari | General Counsel & Chief Compliance Officer |
Ms. Nobuko Kato | Chief Communications Officer |
Mr. Shinichi Teramachi | Corp. Officer, Head of Sales and Head of Japan Sales & Marketing |
Mr. Kenji Morishima | Corporate Officer & Head of China Product Development Department |
Mr. Takahiro Morita | Global Head of Core Principle & Sustainability and Corporate Officer |
Mr. Frank Binder | Corporate Officer & Head of Supply Chain Division |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 13.459 |
---|---|
Trailing PE: | 21.9375 |
Price-to-Book MRQ: | 1.9257 |
Price-to-Sales TTM: | 0.0128 |
IPO Date: | |
Fiscal Year End: | March |
Full Time Employees: | 3744 |